The European cannabis and hemp landscape is evolving rapidly. Between safety opinions issued at the European Union level, increasingly defined national frameworks, and the rise of more concentrated or semi-synthetic products, patients, retailers, and consumers must navigate an increasingly technical environment. By 2026, the issue will no longer be confined to a few niche markets: according to EUDA, 24.9 million European adults are estimated to have used cannabis in the past year, demonstrating the market's scale and the sensitivity of regulatory decisions.
For those involved in the CBD market in France and Europe, the central question is clear: how to distinguish compliant, tested, and properly regulated products from riskier extracts or those with a poor legal standing? This issue also impacts continuity of care for patients, market access regulations for retailers, and road safety for everyone. Here are the key challenges to consider.
European alerts about more potent extracts
On June 9, 2026, EUDA published its European Drug Report with a strong message: the market is evolving rapidly, with increasing availability of more potent substances and more complex uses. In this context, "new cannabis products" are attracting particular attention from public health authorities.
The European agency highlights, in particular, the emergence of semi-synthetic forms observed on the commercial market. This point is crucial, as it serves as a reminder that not all -derived products are equal in terms of risk profile. The difference between a well-documented CBD oil, a technically processed extract, and a more innovative but less transparent formulation can be considerable.
For adult shoppers, this means it becomes even more important to prioritize traceable, lab-tested, and clearly presented products. For reputable retailers, it's also an opportunity: to stand out through transparency, compliance, and truly useful product information.
Dabbing, vaping and high concentrations: why authorities are worried
The EUDA explicitly links certain methods of consuming extracts to increased health risks. "Cannabis dabbing," meaning the inhalation of highly concentrated THC, has been linked to acute poisonings seen in emergency rooms. This is significant: the higher the concentration, the greater the risk of severe adverse effects, especially if the dosage is not properly controlled.
Vaporizers containing cannabis extracts are also mentioned for various risks. Again, everything depends on the actual composition of the product, the quality of its manufacture, the operating temperature, and the possible presence of undesirable compounds. This caution is particularly important at a time when convenient and discreet formats appeal to a wide audience.
The European Drug Report 2026 also points out that the potency of cannabis products circulating in Europe remains high. In 2024, resin seized in the EU contained an average of 24.6% THC, compared to 12% for herbal cannabis. For the general public, these figures demonstrate that the cannabis environment is not static: concentration levels directly influence the risks, the effects experienced, and control policies.
EFSA, novel food and extracts: a concrete challenge for trade
On March 30, 2026, EFSA issued a safety opinion on a CO₂ extract of Cannabis sativa L. used as a novel food. This opinion falls within the scope of Regulation (EU) 2015/2283 and highlights a crucial point: cannabis or hemp extracts are not only examined from a medical or regulatory perspective, but also from a food perspective.
The question of "novel food" status is crucial for retailers. When a product or ingredient falls into this category, its marketing may depend on specific assessment and authorization. A favorable or unfavorable opinion from the EFSA can therefore have a very real impact on the availability of certain extracts, their formulation, and the commercial strategy of sellers in France and the rest of Europe.
For a specialized shop, this means constant vigilance regarding the product categories offered. Not all hemp derivatives can be presented in the same way, let alone accompanied by promises of well-being or health. In practice, regulatory compliance becomes almost as important as the intrinsic quality of the product.
Health claims and reclassification: the retailer's tightrope walk
EUDA reminds consumers that nutritional or health claims on food products containing cannabis or CBD are strictly regulated. Any claim must be authorized under Regulation (EC) No 1924/2006 after scientific evaluation by EFSA. In other words, selling a product is one thing; attributing health effects to it is quite another, and much more strictly regulated.
This distinction is essential to avoid gray areas. A retailer can highlight traceability, composition, analyses, or compliance with legal requirements, but they must remain cautious about implicit or explicit promises. In a highly competitive market, this discipline protects both the company and the consumer.
Another difficulty is that the legal reclassification of cannabidiol-based products varies from country to country. EUDA indicates that several countries have treated CBD as a "cannabis extract," and therefore as a controlled product under the 1961 Convention. For cross-border sales, this is a real headache: a product acceptable in one market may be much more problematic in another.
Medical cannabis : a separate framework from commercial products
At the European level, the distinction between medical, scientific, and other commercial uses remains very clear. EUDA reiterates that, according to international conventions, the cultivation, supply, and possession of cannabis should only be authorized for "medical and scientific purposes." This establishes a clear legal boundary between a medicinal product and a commercial hemp-derived product.
This distinction is a key point in the current debate. Cannabis-based medicines must meet quality, safety, and efficacy requirements for standardized finished products. Conversely, commercial products based on extracts may fall under different legal frameworks, with varying levels of evaluation depending on their intended use, presentation, and composition.
For consumers, this distinction avoids confusion. A wellness product or a collector's item does not have the same status as a medication prescribed to a patient. For responsible retailers, clearly explaining this boundary is essential to properly inform the public without muddying the medical message.
The French framework for medical cannabis in transition
France took a significant step forward when the Ministry of Health announced on March 20, 2025, the notification to the European Commission of the regulations governing medical cannabis. The TRIS dossier confirms that a specific framework is being developed for production and authorization, with a further regulatory shift expected in 2026.
The French system specifies precise pharmaceutical forms, including rapid-acting formulations and tamper-evident, secure, non-refillable, single-dose cartridges. These technical choices are not insignificant: they aim to limit misuse, commercial repackaging, and safety breaches, while ensuring standardized administration for patients.
At the same time, the medical cannabis trial was based on a specific legal framework, with exceptional support for patients still undergoing treatment until March 31, 2026. This highlights a major issue: continuity of care. When a framework changes, patients need visibility, stability, and secure access to their treatments.
Patients, national exceptions and continuity of care
In the absence of marketing authorization, some Member States may allow access to cannabis-based medicinal preparations through national exceptions. EUDA specifies that a patient may, in certain countries, receive an individually prescribed preparation via Article 5 of Directive 2001/83/EC. This mechanism illustrates the extent to which Europe still operates with heterogeneous approaches.
For patients, this diversity can be both a solution and a source of uncertainty. It sometimes allows rapid access to appropriate preparation, but it also complicates the system's clarity, the continuity of treatment when traveling, and the understanding of rights from one country to another.
For professionals and retailers, this situation serves as a reminder to avoid any confusion between commercial support and therapeutic response. The national medical framework can create tension between patient access and market safety, especially when demand is high but quality, safety, and efficacy standards must remain paramount.
Road safety: an often underestimated issue
Road safety remains a major concern regarding cannabis products and psychoactive medications. The EMCDDA points out that, after alcohol, cannabis and benzodiazepines are among the most commonly used psychoactive substances in Europe. These two categories are significant when discussing impaired driving ability.
European authorities also emphasize the importance of informing patients. A pictogram or clear statement about psychoactive medications that can affect driving ability can help prevent risks. This type of information is particularly useful in a context where some people mistakenly believe that a cannabis-derived product is necessarily compatible with driving.
The key message is simple: whenever a product can affect alertness, reflexes, or perception, caution is essential. For patients undergoing treatment as well as consumers of extracts, responsibility means being informed, respecting the guidelines for use, and avoiding driving if in doubt.
Between European opinions on the safety of extracts, the evolving novel food status, the heterogeneity of national regulations, and the framework for medical cannabis in France, the market is entering a more demanding phase of maturity. For patients, the main challenge remains access to safe and continuous solutions. For retailers, it's about offering compliant, traceable products with a clear legal position, without any ambiguity regarding their status.
In this context, transparency remains the best guide. Transparency regarding origin, analysis, composition, regulatory limits, and precautions for use, particularly concerning road safety. As European cannabis policies evolve, the strongest players will be those able to combine education, compliance, and genuine product quality.
